| Dr Paul Mcpherson Johnson, MD | |
|
1199 Prince Ave, Msb 2nd Floor, Athens, GA 30606-2797 | |
| (706) 475-1700 | |
| (706) 475-1790 |
| Full Name | Dr Paul Mcpherson Johnson |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 16 Years |
| Location | 1199 Prince Ave, Athens, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164682134 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0011X | Internal Medicine - Interventional Cardiology | 075306 (Georgia) | Primary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 075306 (Georgia) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Piedmont Athens Regional Medical Center | Athens, GA | Hospital |
| Elbert Memorial Hospital | Elberton, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Piedmont Athens Specialty Care Llc | 8820349772 | 99 |
News Archive
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market preservative-free Methotrexate Injection, USP. APP currently manufactures Methotrexate Injection with preservative.
A new study demonstrates that targeted brain stimulation is effective at dulling social pain.
Altana AG has announced that Alvesco (Ciclesonide), a novel inhaled corticosteroid (ICS) for the treatment of adults (18+ years) suffering from persistent asthma is now available for the first time in the United Kingdom (UK).
› Verified 6 days ago
| Entity Name | Piedmont Cardiology Of Atlanta, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275729691 PECOS PAC ID: 0345321691 Enrollment ID: O20080114000153 |
News Archive
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market preservative-free Methotrexate Injection, USP. APP currently manufactures Methotrexate Injection with preservative.
A new study demonstrates that targeted brain stimulation is effective at dulling social pain.
Altana AG has announced that Alvesco (Ciclesonide), a novel inhaled corticosteroid (ICS) for the treatment of adults (18+ years) suffering from persistent asthma is now available for the first time in the United Kingdom (UK).
› Verified 6 days ago
| Entity Name | Athens Regional Specialty Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083939136 PECOS PAC ID: 8325162340 Enrollment ID: O20100827000645 |
News Archive
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market preservative-free Methotrexate Injection, USP. APP currently manufactures Methotrexate Injection with preservative.
A new study demonstrates that targeted brain stimulation is effective at dulling social pain.
Altana AG has announced that Alvesco (Ciclesonide), a novel inhaled corticosteroid (ICS) for the treatment of adults (18+ years) suffering from persistent asthma is now available for the first time in the United Kingdom (UK).
› Verified 6 days ago
| Entity Name | Piedmont Athens Specialty Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184130627 PECOS PAC ID: 8820349772 Enrollment ID: O20180917001273 |
News Archive
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market preservative-free Methotrexate Injection, USP. APP currently manufactures Methotrexate Injection with preservative.
A new study demonstrates that targeted brain stimulation is effective at dulling social pain.
Altana AG has announced that Alvesco (Ciclesonide), a novel inhaled corticosteroid (ICS) for the treatment of adults (18+ years) suffering from persistent asthma is now available for the first time in the United Kingdom (UK).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paul Mcpherson Johnson, MD Po Box 161435, Atlanta, GA 30321-1435 Ph: (706) 369-5474 | Dr Paul Mcpherson Johnson, MD 1199 Prince Ave, Msb 2nd Floor, Athens, GA 30606-2797 Ph: (706) 475-1700 |
News Archive
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market preservative-free Methotrexate Injection, USP. APP currently manufactures Methotrexate Injection with preservative.
A new study demonstrates that targeted brain stimulation is effective at dulling social pain.
Altana AG has announced that Alvesco (Ciclesonide), a novel inhaled corticosteroid (ICS) for the treatment of adults (18+ years) suffering from persistent asthma is now available for the first time in the United Kingdom (UK).
› Verified 6 days ago
Bannur Ramanna Nandeesh, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1199 Prince Ave, Athens, GA 30606 Phone: 706-475-5076 | |
Krupal Jay Hari, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 242 King Avenue, Suite 210, Athens, GA 30606 Phone: 706-475-1700 Fax: 706-475-1790 | |
Mr. Ashwin Thatti, Internal Medicine Medicare: Medicare Enrolled Practice Location: 1500 Oglethorpe Ave Ste 500c, Athens, GA 30606 Phone: 706-546-7484 | |
Dr. Stephen William Wilde, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 700 Sunset Dr, Suite 501, Athens, GA 30606 Phone: 706-208-0065 Fax: 706-459-8693 | |
Dr. James S Miller, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1199 Prince Ave, Athens, GA 30606 Phone: 706-475-1700 Fax: 706-546-1787 | |
Dr. Paul Peteet, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 55 Carlton St, Athens, GA 30602 Phone: 706-542-8621 Fax: 706-583-0217 | |
Diana T Blake, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2470 Daniells Bridge Rd Ste 231, Athens, GA 30606 Phone: 706-769-3362 Fax: 706-769-5675 |